Articles related to GUIDELINES/RECOMMENDATIONS

The smartwatch market generated approximately 38.6 billion US dollars in revenue globally in 2022, and growth is expected to continue. Over a hundred of these devices, ranging from AI ultrasounds to smart sleep trackers and ECG watches, have been tried and tested by the author. His “7+1” recommendations are listed here.

The update was based on the findings of 31 systematic reviews and 16 randomized controlled trials (RCTs) chosen from a total of 820 publications. The investigators set out to answer seven questions:

In the US, chronic pain is widespread and continues to be a burden for people, families, and society as a whole. Extreme caution should be exercised when choosing to take an opioid to treat pain. The organizations do not advocate the regular use of opiate analgesics to treat chronic pain, as the hazards to the patient outweigh the minimal benefits that opioids may offer. Buprenorphine should be taken into consideration if it is decided to employ long-term opioid therapy for a patient due to its lower risk profile. By checking for underlying mental problems and a history of traumatic brain injury, clinicians can further lower the risk. Although risk mitigation strategies have been used to reduce risk in opioid patients, the guideline development group was surprised to find little evidence in this area.

The assessment of response to radiation-based therapies can be complicated by persistent or changing imaging features, and this field of study is still in active development even though imaging-based response assessment systems have been validated for the evaluation of response to ablative locoregional therapies. Research is still needed to address the shortcomings of current imaging criteria for evaluating tumor response to these novel techniques, despite the increased application of radiation-based local-regional therapies for the treatment of HCC following technological advancements and a better understanding of tumor biology.

The updated guidelines recommend, in brief:

Guideline Central offers a complete summary of the ADA’s latest guideline — Standards of Care for 2023. The update and summary cover topics from delaying the onset of T2DM to supporting positive behaviors, glycemic targets, weigh management, technology, pharmacology, and preventing and managing complications and concomitant diseases.